Skip to main content

Table 4 Analyses of the incidence of pneumonitis using logistic regression models

From: Risk factors for pneumonitis in advanced extrapulmonary cancer patients treated with immune checkpoint inhibitors

Factor

Symptomatic (≥ G2) pneumonitis

All-grade (≥ G1) pneumonitis

Univariate Analysis

Multivariate Analysis

Univariate Analysis

Multivariate Analysis

OR (95% CI)

P-values

HR (95% CI)

P-values

OR (95% CI)

P-values

HR (95% CI)

P-values

LM

 

0.015

 

0.0076

 

0.26

  

  + vs − 

7.58 (1.39–141.38)

 

10.08 (1.69–199.81)

 

1.83 (0.64–6.39)

   

Age

 

0.99

   

0.30

  

  per 1-year increase

0.99 (0.95–1.06)

   

1.02 (0.98–1.08)

   

Sex

 

0.11

   

0.08

  

  Male vs Female

4.18 (0.76–78.27)

   

3.40 (0.89–22.40)

   

Smoking history

  Ever vs Never

3.03 (0.75–20.44)

0.13

  

3.49 (1.06–15.77)

0.038

  

Amount of Smoking (pack-years)

 

0.020

   

0.018

 

0.029

  per 20-pack year increase

20.39 (20.06–20.76)

   

20.35 (20.06–20.68)

 

20.33 (20.03–20.66)

 

BMI (kg/m2)

 

0.90

   

0.99

  

  per 1 kg/m2

1.01 (0.87–1.16)

   

1.00 (0.88–1.12)

   

ILD

 

0.071

 

0.037

 

0.078

 

0.12

  Yes vs No

3.78 (0.88–14.90)

 

6.76 (1.13–40.63)

 

4.33 (0.83–18.88)

 

3.19 (0.72–13.01)

 

Treatment line

 

0.19

   

0.92

  
 

1.36 (0.85–2.12)

   

1.02 (0.66–1.51)

   

  TKI

 

0.19

   

0.92

  

Yes vs No

2.33 (0.64–8.01)

   

1.06 (0.31–3.11)

   

CRP (mg/dl)

 

0.69

   

0.84

  
 

1.04 (0.84–1.23)

   

1.02 (1.18–0.98)

   

NLR

 

0.97

   

0.94

  
 

1.00 (0.83–1.11)

   

1.00 (0.88–1.10)

   
  1. OR Odds ratio, CRP C-reactive protein, CI Confidence interval, BMI Body mass index, HR Hazard ratio, ILD Interstitial lung disease, LM Lung metastasis, TKI Tyrosine kinase inhibitor, NLR Neutrophil-to-lymphocyte ratio
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us